Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)
NCT05915910 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6
Last updated 2024-04-19
Summary
The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.
Conditions
- Glycogen Storage Disease Type IB
Interventions
- DIAGNOSTIC_TEST
-
Specimen Donation
blood donation
Sponsors & Collaborators
-
Sanguine Biosciences
lead INDUSTRY
Eligibility
- Min Age
- 4 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-27
- Primary Completion
- 2024-03-13
- Completion
- 2024-03-13
Countries
- United States
Study Locations
More Related Trials
-
Late-Onset Treatment Study Extension Protocol
NCT00455195 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
NCT00106912 ·Status: COMPLETED
-
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
NCT00059280 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Data Collection in Women With Fabry Disease
NCT00030134 ·Status: COMPLETED
-
Diabetes/ Endocrine Surveillance in SDS
NCT04275479 ·Status: TERMINATED
-
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
NCT06666413 ·Status: RECRUITING ·Phase: PHASE4
-
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
NCT00077662 ·Status: COMPLETED
-
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
NCT00553631 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
NCT04519749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Longitudinal Studies of the Glycoproteinoses
NCT01891422 ·Status: COMPLETED
-
Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
NCT00113035 ·Status: COMPLETED
-
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
NCT00053573 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
NCT02898753 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
NCT02416661 ·Status: COMPLETED
-
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
NCT04999059 ·Status: TERMINATED
-
Registry of Fabry Disease - A Multicenter Observational Study
NCT00055016 ·Status: COMPLETED
-
GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)
NCT05109793 ·Status: COMPLETED
-
Pompe Disease Registry Protocol
NCT00231400 ·Status: RECRUITING
-
Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602
NCT00125879 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
NCT01136304 ·Status: COMPLETED
-
Study of STG-001 in Subjects With Stargardt Disease
NCT04489511 ·Status: COMPLETED ·Phase: PHASE2
-
Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive Testing
NCT05699265 ·Status: TERMINATED
-
T1 Mapping in Fabry Disease
NCT05923788 ·Status: RECRUITING ·Phase: NA